Dice therapeutics 10q
WebDICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings) IRS No.: 472286244 State of Incorp.:DE Fiscal Year End: 1231 Type: S-1MEF Act: 33 ...
Dice therapeutics 10q
Did you know?
WebAbout – DICE THERAPEUTICS. We are led by an exceptional team of scientists, R&D executives and company builders with demonstrated track records of progressing … WebAug 11, 2024 · Inside Dice Therapeutics, Inc.'s 10-Q Quarterly Report: Financial - Expense Highlight. The increase of $5.1 million and $9.1 million for the three and six months ended June 30, 2024, respectively, was primarily due to increases in personnel-related expenses of $3.0 million and $4.5 million, respectively, resulting from an increase in headcount ...
WebJan 24, 2024 · Financials. According to the 10-Q SEC Filing, DICE Therapeutics had cash, cash equivalents and marketable securities of $266.6 million as of September 30, 2024. This was an okay amount of cash ... WebNov 9, 2024 · The Investor Relations website contains information about DICE Therapeutics's business for stockholders, potential investors, and financial analysts.
WebSep 30, 2024 · false Q3--12-31 0001645569 P2Y P2M P4Y P6Y1M6D P6Y1M6D P5Y6M P6Y1M6D P5Y6M P6Y1M6D 0.75 0.80 0.0074 0.0074 0.0042 0.0082 0.0110 0.0173 P9Y11M12D P9Y11M12D P5Y P6Y8M12D P5Y P6Y8M12 WebApr 1, 2024 · DICE Therapeutics Stock Performance. Shares of DICE opened at $28.67 on Friday. DICE Therapeutics has a 52-week low of $12.64 and a 52-week high of $45.99. The firm has a market cap of $1.37 billion, a price-to-earnings ratio of -13.40 and a beta of 0.71. The business's fifty day moving average is $29.47 and its 200-day moving average is …
WebDICE Therapeutics Inc. SEC filings breakout by MarketWatch. View the DICE U.S. Securities and Exchange Commission reporting information.
WebNov 9, 2024 · Dice Therapeutics, Inc. (DICE) SEC Filing 10-Q Quarterly Report for the period ending Friday, September 30, 2024 hillsborough county property homesteadWebPioneers in small molecule drug development. Our mission is to become an industry leader in creating transformative small molecule medicines for autoimmune and inflammatory … hillsborough county probation recordsWebAnnual report which provides a comprehensive overview of the company for the past year. 10-K. Annual Filings. 0000950170-23-008119.pdf. 0000950170-23-008119.rtf. … hillsborough county property folio numberWebDec 31, 2024 · You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on … smart home battery cameraWebOct 11, 2024 · About DICE Therapeutics, Inc. ... risks and uncertainties described under the heading “Risk Factors” in the Company’s quarterly report on Form 10-Q filed on … smart home bauconsultingWebDICE Therapeutics. 4,014 followers. 7mo. We are pleased to announce the completion of enrollment in our Phase 1 clinical trial of DC-806. DC-806 is an orally-available, small molecule antagonist ... hillsborough county property liensWebDec 31, 2024 · DICE. The Nasdaq Stock Market LLC ... We are initially focused on developing oral therapeutics against well-validated targets in immunology, with the goal of achieving comparable potency to their systemic biologic counterparts, which have demonstrated the greatest therapeutic benefit to date in these disease areas. Our … smart home bauhaus